Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25025847 | 0.84 | FFAR4 (0.35) | PIM1 | |
| SCHEMBL25564727 | 0.84 | FFAR4 (0.35) | PIM1 | |
| SCHEMBL23177943 | 0.80 | KDM4E (0.36) | — | |
| SCHEMBL5235702 | 0.77 | — | — | |
| SCHEMBL31299462 | 0.76 | APLNR (0.50) | APLNR | |
| SCHEMBL26906347 | 0.75 | TSHR (0.33) | — | |
| SCHEMBL23323295 | 0.75 | SLC6A4 (0.31) | PIM1 | |
| SCHEMBL19246098 | 0.75 | APLNR (0.35) | APLNRTRPA1 | |
| SCHEMBL23323125 | 0.75 | SLC6A4 (0.31) | PIM1 | |
| SCHEMBL21101827 | 0.75 | CYP1A2 (0.47) | PIM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | HALIA THERAPEUTICS INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | Halia Therapeutics, Inc. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-111233863-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| EP-3205652-B1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-108348525-B | Medical application of hydroxyl purine compound | 广东众生睿创生物科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-111233863-A | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-105566324-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-04-03 | — | — | CN | disclosed |
| CN-110325522-A | Liquid crystal compounds | 默克专利股份有限公司 | 2019-10-11 | — | — | CN | disclosed |
| CN-108348525-A | The medical usage of oxipurinol class compound | 广东众生药业股份有限公司 | 2018-07-31 | — | — | CN | disclosed |
| US-9845308-B2 | Isoindoline inhibitors of ROR-gamma | VITAE PHARMACEUTICALS, INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| CN-107001371-A | Oxipurinol class compound and its application | 广东众生药业股份有限公司 | 2017-08-01 | — | — | CN | disclosed |
| WO-2017071606-A1 | MEDICAL USE OF HYDROXYL PURINE COMPOUND | 南京明德新药研发股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2016-05-05 | — | — | US | disclosed |
| WO-2016054971-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | 南京明德新药研发股份有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160122318-A1 | ISOINDOLINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | APLNR 3696/4885TRPA1 1623/4885NR1H2 5/4885 |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | APLNR 4138/4885TRPA1 3239/4885NR1H2 1428/4885 |
| US-20230183217-A1 | INHIBITORS OF LRRK2 KINASE | LRRK2, SNCA, PRKAR2B | APLNR 4539/4885TRPA1 3357/4885NR1H2 3827/4885 |
| US-11578061-B2 | Inhibitors of LRRK2 kinase | LRRK2, SNCA, PRKAR2B | APLNR 4539/4885TRPA1 3357/4885NR1H2 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.